site logo

Cortexyme drug fails in Alzheimer's trial, but company sees validation of unorthodox approach

The treatment missed both primary goals of a late-stage study. Signs of benefit in a subgroup, however, have Cortexyme planning next steps.

Permission granted by Cortexyme